<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768560</url>
  </required_header>
  <id_info>
    <org_study_id>13012</org_study_id>
    <nct_id>NCT00768560</nct_id>
  </id_info>
  <brief_title>Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study</brief_title>
  <official_title>Evaluation of the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of BAY A1040 CR Tablet on High Dose Administration in Patients With Essential Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, 6 x 3 cross-over study. All patients who
      meet the entry criteria will be required to stop taking any other anti-hypertensive agents
      than Adalat CR (controlled release), if taken, before starting 4 weeks (±7days) open-label
      Adalat CR 40 mg once daily (OD) treatment phase (baseline treatment period). Of them, those
      who are confirmed with their eligibility as subjects for the present study at the end of the
      baseline treatment period will be randomly allocated to one of the 6 treatment sequences on
      the basis of a computer-generated randomization list. Subsequently, BAY A1040 CR tablet 40 mg
      OD, 40 mg twice daily (BID) or 80 mg OD will be administered to a total of 6 weeks, 2 weeks
      per each treatment period (Period 1-3) under double-blind conditions using BAY A1040 CR
      tablet 40 mg and its placebo as follows (Double-blind treatment period).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Issues on safety are addressed in the Adverse Event section.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Sitting Blood Pressure</measure>
    <time_frame>Baseline and after 2 weeks treatment</time_frame>
    <description>Changes of sitting SBP and DBP (trough values) from baseline (ie [trough BP at the end of each period during the double-blind treatment period] minus [trough BP at the end of the baseline treatment period])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences of Systolic Blood Pressure Profile</measure>
    <time_frame>Baseline and after 2 weeks treatment</time_frame>
    <description>Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences of Diastolic Blood Pressure Profile</measure>
    <time_frame>Baseline and after 2 weeks treatment</time_frame>
    <description>Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Blood Pressure Achievement in Elderly (≥65)</measure>
    <time_frame>After 2 weeks treatment</time_frame>
    <description>Elderly subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP &lt;140 mm Hg and DBP &lt;90 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Blood Pressure Achievement in Non-elderly (&lt;65)</measure>
    <time_frame>After 2 weeks treatment</time_frame>
    <description>Non-elderly subjects (&lt;65 years) without diabetes mellitus or chronic renal disorder and target BP SBP &lt;130 mm Hg and DBP &lt;85 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder</measure>
    <time_frame>After 2 weeks treatment</time_frame>
    <description>Subjects with diabetes mellitus or chronic renal disorders and target BP SBP &lt;130 mm Hg and DBP &lt;80 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Blood Pressure Achievement in All Subjects</measure>
    <time_frame>After 2 weeks treatment</time_frame>
    <description>Subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP &lt;140 mm Hg and DBP &lt;90 mm Hg. Subjects (&lt;65 years) without diabetes mellitus or chronic renal disorder and target BP SBP &lt;130 mm Hg and DBP &lt;85 mm Hg. Subjects with diabetes mellitus or chronic renal disorders and target BP SBP &lt;130 mm Hg and DBP &lt;80 mm Hg.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine (Adalat CR, BAYA1040) 80mg OD</intervention_name>
    <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
    <arm_group_label>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine (Adalat CR, BAYA1040) 40mg BID</intervention_name>
    <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
    <arm_group_label>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine (Adalat CR, BAYA1040) 40mg OD</intervention_name>
    <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
    <arm_group_label>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female

          -  20 years or older and less than 75 years

          -  Outpatient

          -  Untreated or treated patients with antihypertensive agents whose blood pressure (BP)
             in sitting position at entry (Visit 1) is as follows.

               -  Untreated patients: systolic blood pressure (SBP) &gt;= 160mmHg or diastolic blood
                  pressure (DBP) &gt;= 100mmHg

               -  Treated patients: SBP &gt;= 140mmHg or DBP &gt;= 90mmHg (at trough)

        Exclusion Criteria:

          -  Patients whose BP during baseline treatment period is: SBP&gt;=200mmHg or DBP&gt;=120mmHg.

          -  Patients with secondary hypertension or hypertensive emergency.

          -  Patients with cardiovascular or cerebrovascular ischemic event (stroke, transient
             ischemic attack (TIA), myocardial infarction or unstable angina), or with history of
             these within 6 months prior to the study.

          -  Patients with intracranial or subarachnoid hemorrhage, or with history of these within
             6 months prior to the study.

          -  Patients with server hematopoietic dysfunction (acute/chronic leukemia, myeloma,
             malignant lymphoma, myelodysplastic syndrome, aplastic anemia), or with history of
             these.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>982-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koshigaya</city>
        <state>Saitama</state>
        <zip>343-0827</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <results_first_submitted>September 28, 2009</results_first_submitted>
  <results_first_submitted_qc>January 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 2, 2010</results_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>47 subjects were recruited from 30 Jan 2008 to 11 May 2008 by 3 centers in Japan.</recruitment_details>
      <pre_assignment_details>After a 4-week baseline treatment with Adalat controlled release (CR) 40 mg once daily (OD), 35 subjects were randomized to double-blind treatment and were included in the safety analysis. 34 subjects were included in the analysis of pharmacokinetics, efficacy and demographic data. 1 subject discontinued the study in Period 1 due to adverse event.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks Each</title>
        </group>
        <group group_id="P2">
          <title>Nifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks Each</title>
        </group>
        <group group_id="P3">
          <title>Nifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks Each</title>
        </group>
        <group group_id="P4">
          <title>Nifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks Each</title>
        </group>
        <group group_id="P5">
          <title>Nifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks Each</title>
        </group>
        <group group_id="P6">
          <title>Nifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention Set 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5">3-period/treatment crossover</participants>
                <participants group_id="P2" count="6">3-period/treatment crossover</participants>
                <participants group_id="P3" count="6">3-period/treatment crossover</participants>
                <participants group_id="P4" count="6">3-period/treatment crossover</participants>
                <participants group_id="P5" count="6">3-period/treatment crossover</participants>
                <participants group_id="P6" count="6">3-period/treatment crossover</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="5">40 mg OD for 2 weeks</participants>
                <participants group_id="P2" count="6">40 mg OD for 2 weeks</participants>
                <participants group_id="P3" count="6">40 mg twice daily (BID) for 2 weeks</participants>
                <participants group_id="P4" count="6">40 mg BID for 2 weeks</participants>
                <participants group_id="P5" count="6">80 mg OD for 2 weeks</participants>
                <participants group_id="P6" count="6">80 mg OD for 2 weeks</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Intervention Set 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5">40 mg BID for 2 weeks</participants>
                <participants group_id="P2" count="5">80 mg OD for 2 weeks</participants>
                <participants group_id="P3" count="6">80 mg OD for 2 weeks</participants>
                <participants group_id="P4" count="6">40 mg OD for 2 weeks</participants>
                <participants group_id="P5" count="6">40 mg OD for 2 weeks</participants>
                <participants group_id="P6" count="6">40 mg BID for 2 weeks</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention Set 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5">80 mg OD for 2 weeks</participants>
                <participants group_id="P2" count="5">40 mg BID for 2 weeks</participants>
                <participants group_id="P3" count="6">40 mg OD for 2 weeks</participants>
                <participants group_id="P4" count="6">80 mg OD for 2 weeks</participants>
                <participants group_id="P5" count="6">40 mg BID for 2 weeks</participants>
                <participants group_id="P6" count="6">40 mg OD for 2 weeks</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nifedipine 40 mg OD x 40 mg BID x 80 mg OD for 2 Weeks Each</title>
        </group>
        <group group_id="B2">
          <title>Nifedipine 40 mg OD x 80 mg OD x 40 mg BID for 2 Weeks Each</title>
        </group>
        <group group_id="B3">
          <title>Nifedipine 40 mg BID x 80 mg OD x 40 mg OD for 2 Weeks Each</title>
        </group>
        <group group_id="B4">
          <title>Nifedipine 40 mg BID x 40 mg OD x 80 mg OD for 2 Weeks Each</title>
        </group>
        <group group_id="B5">
          <title>Nifedipine 80 mg OD x 40 mg OD x 40 mg BID for 2 Weeks Each</title>
        </group>
        <group group_id="B6">
          <title>Nifedipine 80 mg OD x 40 mg BID x 40 mg OD for 2 Weeks Each</title>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" lower_limit="55" upper_limit="68"/>
                    <measurement group_id="B2" value="63.6" lower_limit="55" upper_limit="73"/>
                    <measurement group_id="B3" value="59.7" lower_limit="55" upper_limit="65"/>
                    <measurement group_id="B4" value="64.3" lower_limit="60" upper_limit="70"/>
                    <measurement group_id="B5" value="58.2" lower_limit="37" upper_limit="67"/>
                    <measurement group_id="B6" value="59.7" lower_limit="56" upper_limit="68"/>
                    <measurement group_id="B7" value="61.1" lower_limit="37" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Pressure (Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)) at Baseline</title>
          <description>Blood pressure (BP) before the start of baseline treatment. Subjects valid for safety analysis</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>SBP at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150.00" spread="7.91"/>
                    <measurement group_id="B2" value="161.00" spread="16.67"/>
                    <measurement group_id="B3" value="156.33" spread="11.18"/>
                    <measurement group_id="B4" value="155.83" spread="10.96"/>
                    <measurement group_id="B5" value="156.33" spread="14.79"/>
                    <measurement group_id="B6" value="154.83" spread="13.53"/>
                    <measurement group_id="B7" value="155.89" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.40" spread="4.98"/>
                    <measurement group_id="B2" value="95.00" spread="6.60"/>
                    <measurement group_id="B3" value="98.00" spread="6.45"/>
                    <measurement group_id="B4" value="91.00" spread="7.07"/>
                    <measurement group_id="B5" value="92.50" spread="3.45"/>
                    <measurement group_id="B6" value="89.83" spread="7.68"/>
                    <measurement group_id="B7" value="93.43" spread="6.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart rate (HR) at Baseline</title>
          <description>Heart rate (HR) before the start of baseline treatment. Subjects valid for safety analysis</description>
          <units>beats / min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.20" spread="6.18"/>
                    <measurement group_id="B2" value="72.67" spread="13.95"/>
                    <measurement group_id="B3" value="79.00" spread="10.81"/>
                    <measurement group_id="B4" value="70.83" spread="5.42"/>
                    <measurement group_id="B5" value="68.50" spread="7.87"/>
                    <measurement group_id="B6" value="79.50" spread="17.84"/>
                    <measurement group_id="B7" value="72.69" spread="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Sitting Blood Pressure</title>
        <description>Changes of sitting SBP and DBP (trough values) from baseline (ie [trough BP at the end of each period during the double-blind treatment period] minus [trough BP at the end of the baseline treatment period])</description>
        <time_frame>Baseline and after 2 weeks treatment</time_frame>
        <population>Per-protocol efficacy population: subjects valid for safety analysis who have no critical protocol deviation and have trough BP at the end of baseline treatment period and trough BP at the end of period 1 are considered valid for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
          </group>
          <group group_id="O3">
            <title>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Sitting Blood Pressure</title>
          <description>Changes of sitting SBP and DBP (trough values) from baseline (ie [trough BP at the end of each period during the double-blind treatment period] minus [trough BP at the end of the baseline treatment period])</description>
          <population>Per-protocol efficacy population: subjects valid for safety analysis who have no critical protocol deviation and have trough BP at the end of baseline treatment period and trough BP at the end of period 1 are considered valid for the analysis.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.19" spread="1.24"/>
                    <measurement group_id="O2" value="-19.88" spread="1.24"/>
                    <measurement group_id="O3" value="-10.13" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.30" spread="0.65"/>
                    <measurement group_id="O2" value="-8.28" spread="0.65"/>
                    <measurement group_id="O3" value="-4.98" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The point estimate and 90% confidence interval of the difference of changes in SBP from baseline was estimated by using the analysis of variance (ANOVA) model including the terms: group, subject within a group, dosage and administration and stage as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-12.62</ci_lower_limit>
            <ci_upper_limit>-6.77</ci_upper_limit>
            <estimate_desc>40 mg BID minus 40 mg OD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The point estimate and 90% confidence interval of the difference of changes in SBP from baseline was estimated by using the ANOVA model including the terms: group, subject within a group, dosage and administration and stage as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-2.87</ci_lower_limit>
            <ci_upper_limit>2.98</ci_upper_limit>
            <estimate_desc>80 mg OD minus 40 mg OD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The point estimate and 90% confidence interval of the difference of changes in SBP from baseline was estimated by using the ANOVA model including the terms: group, subject within a group, dosage and administration and stage as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.75</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>6.83</ci_lower_limit>
            <ci_upper_limit>12.67</ci_upper_limit>
            <estimate_desc>80 mg OD minus 40 mg BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The point estimate and 90% confidence interval of the difference of changes in DBP from baseline was estimated by using the ANOVA model including the terms: group, subject within a group, dosage and administration and stage as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.97</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-5.50</ci_lower_limit>
            <ci_upper_limit>-2.44</ci_upper_limit>
            <estimate_desc>40 mg BID minus 40 mg OD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The point estimate and 90% confidence interval of the difference of changes in DBP from baseline was estimated by using the ANOVA model including the terms: group, subject within a group, dosage and administration and stage as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-2.21</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>80 mg OD minus 40 mg OD</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The point estimate and 90% confidence interval of the difference of changes in DBP from baseline was estimated by using the ANOVA model including the terms: group, subject within a group, dosage and administration and stage as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>4.82</ci_upper_limit>
            <estimate_desc>80 mg OD minus 40 mg BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences of Systolic Blood Pressure Profile</title>
        <description>Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)</description>
        <time_frame>Baseline and after 2 weeks treatment</time_frame>
        <population>Subjects valid for efficacy analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
          </group>
          <group group_id="O3">
            <title>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Differences of Systolic Blood Pressure Profile</title>
          <description>Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)</description>
          <population>Subjects valid for efficacy analysis</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 0-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.35" spread="15.75"/>
                    <measurement group_id="O2" value="-21.24" spread="11.56"/>
                    <measurement group_id="O3" value="-9.91" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.91" spread="11.62"/>
                    <measurement group_id="O2" value="-8.65" spread="11.19"/>
                    <measurement group_id="O3" value="-11.97" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.18" spread="12.05"/>
                    <measurement group_id="O2" value="-5.76" spread="11.25"/>
                    <measurement group_id="O3" value="-7.85" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.56" spread="12.58"/>
                    <measurement group_id="O2" value="-4.94" spread="9.31"/>
                    <measurement group_id="O3" value="-7.26" spread="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 8-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.88" spread="11.53"/>
                    <measurement group_id="O2" value="-6.97" spread="10.23"/>
                    <measurement group_id="O3" value="-7.88" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 10-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.79" spread="10.60"/>
                    <measurement group_id="O2" value="-4.03" spread="10.64"/>
                    <measurement group_id="O3" value="-6.56" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.59" spread="10.98"/>
                    <measurement group_id="O2" value="-4.38" spread="9.31"/>
                    <measurement group_id="O3" value="-6.00" spread="9.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 24-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.97" spread="12.79"/>
                    <measurement group_id="O2" value="-18.38" spread="8.34"/>
                    <measurement group_id="O3" value="-10.21" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences of Diastolic Blood Pressure Profile</title>
        <description>Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)</description>
        <time_frame>Baseline and after 2 weeks treatment</time_frame>
        <population>Subjects valid for efficacy analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
          </group>
          <group group_id="O3">
            <title>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Differences of Diastolic Blood Pressure Profile</title>
          <description>Differences in blood pressure at the same time points (0, 2, 4, 6, 8, 10, 12, 24-hour post-dose) between 2 different days (ie, end of baseline treatment period and end of 2-week treatment period)</description>
          <population>Subjects valid for efficacy analysis</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 0-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.82" spread="6.40"/>
                    <measurement group_id="O2" value="-8.12" spread="6.24"/>
                    <measurement group_id="O3" value="-4.18" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.15" spread="7.27"/>
                    <measurement group_id="O2" value="-5.47" spread="7.01"/>
                    <measurement group_id="O3" value="-7.18" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4-hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.44" spread="7.47"/>
                    <measurement group_id="O2" value="-1.62" spread="8.11"/>
                    <measurement group_id="O3" value="-3.68" spread="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.56" spread="7.42"/>
                    <measurement group_id="O2" value="-1.71" spread="7.20"/>
                    <measurement group_id="O3" value="-3.85" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 8-hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.09" spread="6.13"/>
                    <measurement group_id="O2" value="-3.18" spread="6.26"/>
                    <measurement group_id="O3" value="-4.74" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 10-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="6.34"/>
                    <measurement group_id="O2" value="-1.74" spread="6.42"/>
                    <measurement group_id="O3" value="-3.82" spread="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12-hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="6.59"/>
                    <measurement group_id="O2" value="-2.15" spread="7.30"/>
                    <measurement group_id="O3" value="-3.15" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 24-hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.00" spread="7.34"/>
                    <measurement group_id="O2" value="-8.47" spread="5.39"/>
                    <measurement group_id="O3" value="-5.82" spread="8.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Blood Pressure Achievement in Elderly (≥65)</title>
        <description>Elderly subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP &lt;140 mm Hg and DBP &lt;90 mm Hg</description>
        <time_frame>After 2 weeks treatment</time_frame>
        <population>Subjects valid for efficacy analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
          </group>
          <group group_id="O3">
            <title>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Target Blood Pressure Achievement in Elderly (≥65)</title>
          <description>Elderly subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP &lt;140 mm Hg and DBP &lt;90 mm Hg</description>
          <population>Subjects valid for efficacy analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Blood Pressure Achievement in Non-elderly (&lt;65)</title>
        <description>Non-elderly subjects (&lt;65 years) without diabetes mellitus or chronic renal disorder and target BP SBP &lt;130 mm Hg and DBP &lt;85 mm Hg</description>
        <time_frame>After 2 weeks treatment</time_frame>
        <population>Subjects valid for efficacy analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
          </group>
          <group group_id="O3">
            <title>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Target Blood Pressure Achievement in Non-elderly (&lt;65)</title>
          <description>Non-elderly subjects (&lt;65 years) without diabetes mellitus or chronic renal disorder and target BP SBP &lt;130 mm Hg and DBP &lt;85 mm Hg</description>
          <population>Subjects valid for efficacy analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder</title>
        <description>Subjects with diabetes mellitus or chronic renal disorders and target BP SBP &lt;130 mm Hg and DBP &lt;80 mm Hg</description>
        <time_frame>After 2 weeks treatment</time_frame>
        <population>Subjects valid for efficacy analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
          </group>
          <group group_id="O3">
            <title>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Target Blood Pressure Achievement in Subjects With Diabetes Mellitus or Chronic Renal Disorder</title>
          <description>Subjects with diabetes mellitus or chronic renal disorders and target BP SBP &lt;130 mm Hg and DBP &lt;80 mm Hg</description>
          <population>Subjects valid for efficacy analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Blood Pressure Achievement in All Subjects</title>
        <description>Subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP &lt;140 mm Hg and DBP &lt;90 mm Hg. Subjects (&lt;65 years) without diabetes mellitus or chronic renal disorder and target BP SBP &lt;130 mm Hg and DBP &lt;85 mm Hg. Subjects with diabetes mellitus or chronic renal disorders and target BP SBP &lt;130 mm Hg and DBP &lt;80 mm Hg.</description>
        <time_frame>After 2 weeks treatment</time_frame>
        <population>Subjects valid for efficacy analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
          </group>
          <group group_id="O2">
            <title>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
          </group>
          <group group_id="O3">
            <title>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</title>
            <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Target Blood Pressure Achievement in All Subjects</title>
          <description>Subjects (≥65 years) without diabetes mellitus or chronic renal disorders and target BP SBP &lt;140 mm Hg and DBP &lt;90 mm Hg. Subjects (&lt;65 years) without diabetes mellitus or chronic renal disorder and target BP SBP &lt;130 mm Hg and DBP &lt;85 mm Hg. Subjects with diabetes mellitus or chronic renal disorders and target BP SBP &lt;130 mm Hg and DBP &lt;80 mm Hg.</description>
          <population>Subjects valid for efficacy analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nifedipine (Adalat CR, BAYA1040) 40 mg OD</title>
          <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning</description>
        </group>
        <group group_id="E2">
          <title>Nifedipine (Adalat CR, BAYA1040) 40 mg BID</title>
          <description>Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening</description>
        </group>
        <group group_id="E3">
          <title>Nifedipine (Adalat CR, BAYA1040) 80 mg OD</title>
          <description>Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lipid metabolism disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

